Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmette–Guérin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer

EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016

(2017) Marko Babjuk et al.   EUROPEAN UROLOGY

Definitions, End Points, and Clinical Trial Designs for Non–Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group

(2016) Ashish M. Kamat et al.   JOURNAL OF CLINICAL ONCOLOGY

Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline

(2016) Sam S. Chang et al.   JOURNAL OF UROLOGY

BCG-refractory vs. BCG-relapsing non–muscle-invasive bladder cancer: A prospective cohort outcomes study

(2015) Harry W. Herr et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Bacillus Calmette-Guérin immunotherapy for genitourinary cancer

(2013) Nilay M. Gandhi et al.   BJU INTERNATIONAL

Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG

(2013) Maurizio Brausi et al.   EUROPEAN UROLOGY

Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance

(2012) Jorg Oddens et al.   EUROPEAN UROLOGY

Use of Fluorescence In Situ Hybridization to Predict Response to Bacillus Calmette-Guérin Therapy for Bladder Cancer: Results of a Prospective Trial

(2012) Ashish M. Kamat et al.   JOURNAL OF UROLOGY

Bacillus Calmette-Guérin With or Without Interferon α-2b and Megadose Versus Recommended Daily Allowance Vitamins During Induction and Maintenance Intravesical Treatment of Nonmuscle Invasive Bladder Cancer

(2010) Kenneth G. Nepple et al.   JOURNAL OF UROLOGY

A multicolour fluorescencein situhybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy

(2009) Jared Whitson et al.   BJU INTERNATIONAL

The prognostic value of cytology and fluorescencein situhybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy

(2009) Spasenija Savic et al.   INTERNATIONAL JOURNAL OF CANCER